Alex Huang, MD
Ophthalmology · San Diego, CANPI 1821246141
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $50,764 of the $78,784 with a category attached, or 64.4%. 15 manufacturers reported payments, led by Topcon Healthcare, Inc. at 50.3% of the total. Reporting peaked in 2022 at $23,266 and has fallen 96.0% since, to $925 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 160 payments — averaging $492.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Topcon Healthcare, Inc.$40K
- AbbVie$11K
- Glaukos Corporation$9K
- Heidelberg Engineering, Inc.$6K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$4K
- W. L. Gore & Associates, Inc.$4K
- plus $5K from 9 others
Across 1 payment — averaging $8785.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$9K
What the payments were for
- Consulting fees$50,76464%
- Speaking & faculty fees$14,35018%
- Travel & lodging$5,4607%
- Food & beverage$8,16510%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Topcon Healthcare, Inc. | 37 | $39,625 |
| AbbVie(2 entities) | 59 | $11,095 |
| Glaukos Corporation | 17 | $9,117 |
| Heidelberg Engineering, Inc. | 7 | $6,374 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $4,000 |
| W. L. Gore & Associates, Inc. | 2 | $3,720 |
| Alcon | 13 | $2,383 |
| Aerie Pharmaceuticals, Inc. | 8 | $1,663 |
| Sight Sciences, Inc. | 6 | $416 |
| Dexcom, Inc. | 1 | $128 |
| NEW World Medical,inc. | 3 | $82 |
| Dompe US, Inc. | 2 | $66 |
| Nova Eye, Inc. | 1 | $64 |
| Bausch & Lomb Americas Inc. | 1 | $27 |
| Novartis | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Spectralis$6,229
- iStent inject W$5,500
- VYZULTA$4,000
- Product in Development$3,720
- LOTEMAX$3,500
- PROLENSA$3,500
- iStent inject Trabecular Micro-Bypass Stent System$3,125
- OCT TRITON$2,500
- XEN$2,130
- Hydrus Microstent$1,700
- VUITY$1,669
- XEN GLAUCOMA TREATMENT SYSTEM$1,574
- DURYSTA$1,132
- Rocklatan$1,000
- ISTALOL$500
- OMNI(R) SURGICAL SYSTEM (US)$219
- NGENUITY$146
- DEXCOM G6 TRANSMITTER$128
- iStent Trabecular Micro-Bypass Stent System$125
How this compares
$78,784 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 396 | $3,439 |
| VyzultaLatanoprostene Bunod | 11 | $3,261 |
| Brimonidine Tartrate | 61 | $2,937 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 132 | $2,472 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,156 |
| Prednisolone Acetate | 36 | $800 |
| Acetazolamide ErAcetazolamide | 14 | $499 |
| Timolol Maleate | 38 | $443 |
| Ofloxacin | 12 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Vyzulta | $27 | $3,26111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.